国际蛋白质学公司将以新的CEO和分销商为主导的模式转向商业诊断. Proteomics International transitions to commercial diagnostics with new CEO and distributor-led model.

基于珀斯的蛋白质国际实验室正在从一个研究专注的实验所转变为一家商业诊断公司, 在新的首席执行官和战略计划下. Perth-based Proteomics International Laboratories is transitioning from a research-focused lab to a commercial diagnostics company under a new CEO and strategic plan. 该公司正在扩大其基于蛋白质组学的测试产品,包括用于预测糖尿病相关病和子宫内膜异位症PromarkerEndo的PromarkerD. The company is scaling its portfolio of proteomics-based tests, including PromarkerD for predicting diabetes-related kidney disease and PromarkerEndo for endometriosis. 通过使用分销商主导的模式,Proteomics计划在澳大利亚和美国推出这些测试并于2017财年开始提交退款申请,将28财年作为增长突破的一年. By using a distributor-led model, Proteomics aims to launch these tests and initiate reimbursement submissions in Australia and the U.S. by FY27, targeting FY28 as a breakout year for growth.